The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex.
Tag Archive for: generic drugs
Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations.
Resilience of global supply chains was heavily tested during the COVID pandemic. Several processes were enhanced to address unforeseen exigencies, and mitigation strategies were re-assessed. The recent conflict has, however, brought in a renewed sense of urgency.
A group of major pharmaceutical companies want an appeals court to force Connecticut and other states to remain in a coordinated legal proceeding over generic drug pricing, arguing that allowing them to pursue their claims separately would upend years of legal work and cause delays.
Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version.
The Chicago-based drugmaker has been counting on revenues from its newer immunology medicines to help make up for declining sales of its blockbuster arthritis drug Humira.
Despite strong sales of its blockbuster drug Dupixent, Sanofi reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.
The world’s largest generic drugs maker announced on Wednesday that it will divest its active pharmaceutical ingredient (API) unit to focus on its core business.
For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.
Sun Pharma first moved to acquire Taro in May 2007, at the time offering $454 million or $7.75 per share.
